VV

VVY

VVY

Vol

SEC Reports2

Press Releases2

Recent Activity

Jun 8, 2026 SEC

Vivoryon Therapeutics announced it will report Q1 2026 financial results on June 11, 2026, but this is an announcement o

PRESS-RELEASE — Impact 2/10

Jun 8, 2026 earnings

Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026

<p align="center"><b>Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results </b><br><b>on Ju

Apr 23, 2026 SEC

Vivoryon Therapeutics reported full-year 2025 financial results with no revenue, reduced R&D and G&A expenses, and a nar

PRESS-RELEASE — Impact 5/10

Apr 15, 2026 Press

Vivoryon Therapeutics N.V. announced it will report full year 2025 financial results and business updates on April 23, 2

Apr 9, 2026 Press

Vivoryon Therapeutics announced that its COO, Dr. Julia Neugebauer, will participate in the Van Lanschot Kempen Life Sci

Latest Reports

NEUTRAL PRESS-RELEASE 2/10

Vivoryon Therapeutics announced it will report Q1 2026 financial results on June 11, 2026, but this is an announcement o

MIXED PRESS-RELEASE 5/10

Vivoryon Therapeutics reported full-year 2025 financial results with no revenue, reduced R&D and G&A expenses, and a nar

NEUTRAL Press 2/10

Vivoryon Therapeutics N.V. announced it will report full year 2025 financial results and business updates on April 23, 2

∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

2 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 1 neutral. Avg impact: 3.5/10.

NEUTRAL PRESS-RELEASE 2/10

Vivoryon Therapeutics announced it will report Q1 2026 financial results on June 11, 2026, but this

MIXED PRESS-RELEASE 5/10

Vivoryon Therapeutics reported full-year 2025 financial results with no revenue, reduced R&D and G&A

Vivoryon Therapeutics N.V. announced it will report full year 2025 financial results and business up

Vivoryon Therapeutics announced that its COO, Dr. Julia Neugebauer, will participate in the Van Lans

∅

No analyst rating data available yet. Consensus ratings and individual firm actions are collected periodically from financial data providers.

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 8, 2026

earnings

Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026

<p align="center"><b>Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results </b><br><b>on June 11, 2026</b></p>

Apr 23, 2026

earnings

Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update

<p align="center"><b>Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results </b><br><b>and Provides Business Update</b></p>

Apr 15, 2026

announcement

Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026

<p align="center"><b>Vivoryon Therapeutics N.V. to </b><b>Report </b><b>Full Year 2025 Financial Results and Business Updates</b> <b>on April 23, 2026

Apr 9, 2026

announcement

Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference

Vivoryon attend the Van Lanschot Kempen Life Sciences Conference.

Mar 28, 2026

announcement

Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology

New data analyses from the Company’s varoglutamstat Phase 2 program were presented at the World Congress of Nephrology.